Get the Stockscreener App
487.54
0.30%
-1.47
Pre-market:
487.54
Overview
News
Price History
Option Chain
Financials
Why TMO Down?
Discussions
Forecast
Stock Split
Dividend History
Thermo Fisher Scientific Inc stock is traded at $487.54, with a volume of 2.20M.
It is down -0.30% in the last 24 hours and up +17.55% over the past month.
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year end-2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).
See More
Previous Close:
$489.01
Open:
$490.13
24h Volume:
2.20M
Relative Volume:
0.83
Market Cap:
$184.10B
Revenue:
$43.21B
Net Income/Loss:
$6.58B
P/E Ratio:
28.20
EPS:
17.29
Net Cash Flow:
$6.17B
1W Performance:
+5.44%
1M Performance:
+17.55%
6M Performance:
-6.80%
1Y Performance:
-19.28%
1-Day Range:
$487.14
$493.24
1-Week Range:
$460.91
$493.24
52-Week Range:
$385.46
$627.88
Thermo Fisher Scientific Inc Stock (TMO) Company Profile
Name
Thermo Fisher Scientific Inc
Sector
Industry
Phone
(781) 622-1000
Address
168 THIRD AVENUE, WALTHAM, MA
Compare TMO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TMO
Thermo Fisher Scientific Inc
|
487.54 | 184.66B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
209.01 | 151.04B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
637.86 | 52.07B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
118.15 | 33.86B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
192.54 | 32.49B | 15.70B | 1.24B | 2.01B | 6.91 |
Thermo Fisher Scientific Inc Stock (TMO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-24-25 | Downgrade | HSBC Securities | Buy → Hold |
| Jul-11-25 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Jul-09-25 | Downgrade | UBS | Buy → Neutral |
| Jan-10-25 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Dec-23-24 | Initiated | Scotiabank | Sector Perform |
| Oct-14-24 | Initiated | Redburn Atlantic | Buy |
| Oct-01-24 | Initiated | Stephens | Overweight |
| Aug-28-24 | Initiated | Wells Fargo | Overweight |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Mar-18-24 | Resumed | Citigroup | Neutral |
| Jan-24-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-08-24 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-18-23 | Initiated | HSBC Securities | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Oct-26-23 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Oct-25-23 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Sep-06-23 | Resumed | Citigroup | Buy |
| Jul-19-23 | Initiated | Raymond James | Outperform |
| Jul-19-23 | Reiterated | Robert W. Baird | Outperform |
| Jul-13-23 | Upgrade | Credit Suisse | Neutral → Outperform |
| Apr-04-23 | Reiterated | Barclays | Overweight |
| Dec-14-22 | Initiated | Deutsche Bank | Buy |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-22 | Downgrade | The Benchmark Company | Buy → Hold |
| Aug-25-22 | Initiated | Credit Suisse | Neutral |
| Apr-25-22 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| Jan-26-22 | Resumed | Barclays | Overweight |
| Oct-20-21 | Upgrade | Citigroup | Neutral → Buy |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Jul-16-21 | Initiated | The Benchmark Company | Buy |
| Mar-18-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Mar-03-21 | Initiated | Barclays | Overweight |
| Jan-08-21 | Upgrade | Credit Suisse | Neutral → Outperform |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Dec-02-20 | Initiated | Goldman | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Sep-30-20 | Initiated | Atlantic Equities | Overweight |
| Sep-14-20 | Initiated | Morgan Stanley | Overweight |
| Aug-20-20 | Resumed | JP Morgan | Overweight |
| Jul-15-20 | Upgrade | Cleveland Research | Neutral → Buy |
| Jul-07-20 | Reiterated | Needham | Buy |
| Apr-23-20 | Reiterated | Needham | Buy |
| Jan-31-20 | Reiterated | Needham | Buy |
| Jan-22-20 | Initiated | Credit Suisse | Neutral |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Nov-15-19 | Initiated | Stifel | Buy |
| Jul-25-19 | Reiterated | Needham | Buy |
| Jul-16-19 | Downgrade | Needham | Strong Buy → Buy |
| May-30-19 | Initiated | Wolfe Research | Outperform |
| May-23-19 | Reiterated | Needham | Strong Buy |
| Apr-22-19 | Reiterated | Needham | Strong Buy |
| Apr-16-19 | Reiterated | BofA/Merrill | Buy |
View All
Thermo Fisher Scientific Inc Stock (TMO) Latest News
Stifel Reaffirms Buy on Thermo Fisher (TMO) Despite Price Target Cut - MSN
Wells Fargo Reaffirms ‘Buy’ Rating on Thermo Fisher Scientific Inc. (TMO) - MSN
Top Stock Reports for IBM, Goldman Sachs & Thermo Fisher - The Globe and Mail
Astrotech Corporation Appoints Nihanth Badugu as Chief Operating Officer - GlobeNewswire Inc.
Automated Biological Microscope Market Exclusive Report with - openPR.com
Is Wall Street Bullish or Bearish on Thermo Fisher Scientific Stock? - Yahoo Finance
Thermo Fisher Scientific Inc. (NYSE:TMO) Q1 2025 Earnings Call Transcript - MSN
Saliva-based Screening Market CAGR 7.70% Trends with Thermo - openPR.com
Thermo Fisher Scientific's Strategic Momentum and Institutional Confidence: A Top Buy in the Evolving Biotech Landscape - AInvest
Thermo Fisher Scientific (TMO): A Buy Rating Reinforced by Strategic M&A Adjustments and Strong Earnings Momentum - AInvest
Day 7 of Gains Streak for Thermo Fisher Scientific Stock with 8.9% Return (vs. -5.8% YTD) [8/15/2025] - Trefis
Thermo Fisher's 0.82% Gain on 66th-Ranked $1.2B Volume Driven by FDA-Approved Cancer Diagnostic Expansion - AInvest
Is Thermo Fisher Scientific Inc.’s growth already priced inPortfolio Risk Summary & Expert Curated Trade Ideas - thegnnews.com
Is Wall Street Bullish Or Bearish On Thermo Fisher Scientific Stock? - Barchart.com
Is Now a Good Time to Reenter Thermo Fisher Scientific Inc.2025 Winners & Losers & Reliable Price Action Trade Plans - beatles.ru
Epigenetics Market worth US$4.29 billion in 2030 with 13.9% CAGR | MarketsandMarkets™ - PR Newswire UK
Digital health companies list reveals industry leaders and newcomers in Silicon Valley - The Business Journals
Thermo Fisher Navigates 92nd in $940M Volume Amid FDA Approval and Sanofi Strategic Expansion - AInvest
Syncell and Thermo Fisher Collaborate on High-Resolution Spatial Proteomics Workflow - AInvest
Taiwan's Syncell partners with Thermo Fisher to advance high-resolution spatial proteomics - BioSpectrum Asia
Thermo Fisher teams up with Syncell for spatial proteomics integration - Yahoo Finance
HIV Diagnostics Company Evaluation Report 2025 | Abbott, Siemens Healthineers, and Thermo Fisher Scientific Lead the Market with Innovative Portfolios and Strategic Expansion - Yahoo Finance
Recombinant DNA Technology Market Trends, Dynamic Innovation, - openPR.com
Here's How Much a $1000 Investment in Thermo Fisher Scientific Made 10 Years Ago Would Be Worth Today - Yahoo Finance
Toast, Amazon, Thermo Fisher Scientific And An Industrial Stock On CNBC's 'Final Trades' - Benzinga
Syncell Announces Strategic Co-Marketing Agreement to Advance High-Resolution Spatial Proteomics - Business Wire
Major biopharma firm sells Sunnyvale building in real estate consolidation - The Business Journals
Saudi Arabia Clinical Chemistry Analyzer Market Forecast and Company Analysis Report 2025-2033 Featuring Thermo Fisher Scientific, Abbott, Siemens, Danaher, J&J, Sysmex ADR, HORIBA, Hitachi - GlobeNewswire
Mexico Microcarrier Market Trends and Company Analysis Report 2025-2033 Featuring BD, Thermo Fisher Scientific, Merck, Eppendorf, Danaher, Sartorius, Bio Rad, Corning, Lonza Group, Getinge - Yahoo Finance
Apoptosis Market Future Business Opportunities 2025-2032 | - openPR.com
Heron Therapeutics enters supply agreement with Patheon and Thermo Fisher - Investing.com Nigeria
Thermo Fisher Scientific (TMO) Oncomine Dx Test Gains FDA Approval for NSCLC Treatment - simplywall.st
FDA approves Thermo Fisher’s diagnostic test for new NSCLC treatment - Medical Device Network
US Durable Medical Equipment Market Forecast and Competitive Landscape Report 2025-2033 | Invacare, NOVA, Inogen, Thermo Fisher Scientific, Abbott, Medtronic, Baxter, B. Braun, Boston Scientific, BD - Yahoo Finance
Becton, Dickinson shares rise 1.26% premarket after Thermo Fisher Scientific gets US FDA approval for lung cancer test. - AInvest
Thermo Fisher Scientific: A Premium Growth Story at a Discount Valuation - AInvest
Thermo Fisher: Growth Acceleration And Margin Expansion Should Drive The Upside - Seeking Alpha
Thermo Fisher's Stock Climbs 0.36% on FDA Diagnostic Approval Surges to 119th in Activity with $790M Volume - AInvest
Thermo Fisher Receives FDA Approval for NGS-Based Companion Diagnostic for New Non-Small Cell Lung Cancer Treatment - Business Wire
Microplate Readers Market Growth and Future Scope 2025-2032 | - openPR.com
Thermo Fisher Scientific – Environmental and Process Monitoring Instruments : Quotes, Address, Contact - AZoMining
Do Tariffs and Buyback Completion Signal a New Strategic Phase for Thermo Fisher (TMO)? - simplywall.st
Thermo Fisher Scientific Inc.'s (NYSE:TMO) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum? - 富途牛牛
Thermo Fisher Scientific: A Deep-Value Buy in a Misunderstood Sector - AInvest
Thermo Fisher Stock Set for Further Re-rating as Market Finds Correct Valuation - AInvest
Thermo Fisher: The Rerating Is Just Getting StartedBuy (NYSE:TMO) - Seeking Alpha
Thermo Fisher Scientific Stock (TMO) Opinions on $2 Billion Investment Plan - Quiver Quantitative
Fund Update: FLOSSBACH VON STORCH SE added 1,314,182 shares of THERMO FISHER SCIENTIFIC ($TMO) to their portfolio - Quiver Quantitative
U.S. Active Pharmaceutical Ingredients CDMO Market Report 2025-2030 | Competitive Analysis of Thermo Fisher Scientific, Novo Group, Cambrex, Piramal, Corden, Siegfried, Seqens, SK, Noramco, BSP - GlobeNewswire
Thermo Fisher shells out $97m to expand clinical research labs - BioXconomy
Thermo Fisher Tumbles 3.75% on $1.15B Volume Ranks 72nd in Market Activity Amid Mixed Q2 Results and Revised Guidance - AInvest
Thermo Fisher Scientific Inc Stock (TMO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.91%
0.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):